What Happened to COVID-19 Testing?
In recent weeks COVID-19 testing has reduced significantly, which many attribute to the rise in vaccinations. But positivity rates are ...
Patient Cyber Narratives
Healthcare will become more decentralized and populist post-pandemic. With patients relying upon digital and internet-based tools to seek medical care ...
Taxing Healthcare Behavior
If we have learned anything from the pandemic, it is that healthcare is linked to all aspects of society, and ...
The Pandemic May End Soon – That’s the Problem
With the pandemic ending, we are beginning to predict the future of healthcare and society. But the future never follows ...
Pandemic’s Ecological Fallacy
The pandemic ushered in clinical studies that have changed healthcare policy. But the pace of publications also led to studies ...
War Elephants of Healthcare
The original battle tanks of antiquity, war elephants were famed for the terror they inflicted on the battlefield. And equally ...
Anatomy of a DEA Investigation
As the opioid epidemic rages on, DEA agents intensify their efforts to curtail the diversion of prescription medications.
Medical Devices are for the Startups
Most new medical devices are designed and developed by startups, only to be acquired by larger medical device corporations when ...
Nonlinear Healthcare Models
For most businesses, the relationship between revenue and cost is defined in a straightforward unit economic model. In healthcare, this ...
When Reddit Comes For Healthcare
We all know the impact Reddit has on the financial world. But how will Reddit's impact appear in the medical ...
There’s a Vaccine For That
The COVIDization of healthcare will usher in new trends in healthcare, the most promising of which is the widespread use ...
Rise of the Medical Licensing Boards
Mostly used to oversee licensing and disciplinary issues, each state's board holds a unique relationship with the state's attorney general's ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more